Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China
01 May 2019 - 9:00PM
Guardion’s Lumega-Z product and MapcatSF
device are key components of its two-pronged evidence-based
protocol for the treatment of a depleted macular protective
pigment, a known risk factor for age-related macular
degeneration
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), an ocular health sciences and technologies company
that develops, formulates and distributes condition-specific
medical foods and testing technologies supported by evidence-based
protocols, today announced that it was recently notified by the
State Intellectual Property Office of the People’s Republic of
China (“China”) that it has been granted trademark registrations in
China for its proprietary medical food, Lumega-Z (Registration No.
27151643), and for its proprietary medical device, the MapcatSF
(Registration No. 27151644).
The trademark registration for Lumega-Z is
effective from November 7, 2018 to November 6, 2028, and the
trademark registration for the MapcatSF is effective from October
28, 2018 to October 27, 2028. The granting of these trademark
registrations in China is an important step in the Company’s
efforts to introduce the Company’s proprietary products and
services to the Chinese marketplace.
Michael Favish, Guardion’s President and Chief
Executive Officer, commenting on the granting of the trademark
registrations in China, stated “We believe that China, with its
large and growing aging population, represents a substantial market
opportunity for us, and the establishment of intellectual property
rights for our products and services in China will help Guardion in
its efforts to gain market acceptance for Lumega-Z and the
MapcatSF. This development is an important first step in what are
expected to be further investments by Guardion in China as we
introduce our products and services to this important and dynamic
market.”
Information and risk factors with respect to
Guardion and its business, including its ability to successfully
develop and commercialize its proprietary products and
technologies, may be obtained in the Company’s filings with the
Securities and Exchange Commission (“SEC”) at www.sec.gov.
About Guardion Health Sciences,
Inc.
Guardion is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product, Lumega-Z, that addresses a depleted
macular protective pigment, a known risk factor for age-related
macular degeneration (“AMD”) and a significant component of
functional vision performance. Guardion Health Sciences, Inc. has
also developed a proprietary medical device, the MapcatSF®, which
accurately measures the macular pigment density, therefore
providing the only two-pronged evidence-based protocol for the
treatment of a depleted macular protective pigment.
About
VectorVision®
VectorVision®, operating through a wholly-owned
subsidiary of the Company, specializes in the standardization of
contrast sensitivity, glare sensitivity, low contrast acuity, and
ETDRS acuity vision testing. Its patented standardization system
provides the practitioner or researcher the ability to delineate
very small changes in visual capability, either as compared to the
population or from visit to visit. VectorVision®’s CSV-1000 device
is considered the standard of care for clinical trials.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company Contact:
Michael Favish
Chief Executive Officer
Telephone: (858) 605-9055 x
201
E-mail: mfavish@guardionhealth.com
Investor Relations Contact:
Matthew Abenante
Porter, LeVay & Rose, Inc.
Telephone: (212) 564-4700
E-mail: matthew@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2024 to May 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From May 2023 to May 2024